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School of Cancer and Imaging Sciences, Paterson Institute for Cancer Research, University of Manchester, Manchester, United KingdomABSTRACT Fibroblast growth factors (FGFs) utilize cell surface heparan sulfate as a coreceptor in the assembly of signaling
complexes with FGF-receptors on the plasmamembrane. Here we undertake a complete thermodynamic characterization of the
assembly of the FGF signaling complex using isothermal titration calorimetry. Heparin fragments of defined length are used as
chemical analogs of the sulfated domains of heparan sulfate and examined for their ability to oligomerize FGF1. Binding is
modeled using the McGhee-von Hippel formalism for the cooperative binding of ligands to a monodimensional lattice. Oligomer-
ization of FGFs on heparin is shown to be mediated by positive cooperativity (a ¼ 6). Heparin octasaccharide is the shortest
length capable of dimerizing FGF1 and on longer heparin chains FGF1 binds with a minimal footprint of 4.2 saccharide units.
The thermodynamics and stoichiometry of the ternary complex suggest that in solution FGF1 binds to heparin in a trans-dimeric
manner before FGFR recruitment.INTRODUCTIONMammalian fibroblast growth factors (FGFs) are a family of
22 highly conserved polypeptides. They are involved in
a plethora of biological processes, including cell prolifera-
tion, differentiation, cell migration, and angiogenesis
(1,2). FGFs signal through four FGF receptors
(FGFR1–4), which are high affinity cell surface receptor
tyrosine kinases (3). FGFRs have three extracellular immu-
noglobulin-like domains (D1, D2, and D3), of which only
D2 and D3 are required for FGF binding (4). Receptors
1–3 undergo alternative mRNA splicing to generate b- and
c-isoforms with altered ligand specificities and affinities
(5). FGF1 is capable of binding all receptor isoforms, and
is sometimes regarded as the universal ligand (6,7).
Heparan sulfate (HS), a glycosaminoglycan present in the
extracellular matrix and uniformly distributed around virtu-
ally all mammalian cells, is essential for FGF signaling (8).
HS contains linear regions of 50–150 repeating disaccha-
rides of N-acetyl- or N-sulfoglucosamine and uronic acid
joined by (1/4) linkages (9) with typical concentrations
of HS on the cell surface in the range of 105–106 molecules
cell1 (10). The length of an extended HS chain with
average molecular mass of 30 kDa would be ~50 nm (11).
It is variably polysulfated with highly sulfated residues ex-
isting predominantly in contiguous regions (6–14 units), or
S-domains (12). Although heparin is used as a functionalSubmitted August 17, 2012, and accepted for publication February 25,
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sulfated than the majority of S-domain sequences (13).
Heparin is sufficient to promote the mitogenic action of
FGFs on cells deficient in HS (14) and also protects FGFs
from proteolysis and thermal denaturation (15,16). FGFs
vary in their specificities for different HS sulfation patterns,
with heparin being a particularly good analog for FGF1,
which requires N, 2-O, and 6-O sulfate groups for both
high affinity binding and activation (17).
FGF1 adopts a b-trefoil fold with pseudo-threefold
symmetry (18). The crystal structures of FGF2 bound to
heparin tetra- and hexasaccharide (PDB: 1BFB and PDB:
1BFC) (19) and the NMR structure of FGF1 complexed to
a hexasaccharide (PDB: 2ERM) (20) reveal that the
heparin-binding region consists of three surface loops
(Fig. 1 a). FGF interaction with heparin is achieved through
sulfate groups and does not induce any significant confor-
mational change in FGF upon binding, although a distortion
of the heparin helix is a common observation (21). Heparin
decasaccharide was shown to dimerize FGF1 in a trans
configuration with two FGF1 polypeptides related by a quasi
21 symmetry axis that runs perpendicular to the helical axis
of the intercalated heparin molecule (Fig. 1 b) (22). The
complex is characterized by a complete absence of FGF-
FGF interactions as all contacts are mediated through the
heparin molecule.
Formation of a ternary complex in which the FGF recep-
tors are both dimerized and activated is necessary for
signaling to occur. Two crystal structures of a ternary
complex between FGF, FGFR (extracellular domains D2
and D3), and heparin have been determined, each of which
contains a common substructure with 1:1:1 stoichiometry
(23,24). In this 1:1:1 substructure, FGF interacts extensively
with D2 and D3 as well as the highly conserved linker
between the two domains, and heparin interacts withhttp://dx.doi.org/10.1016/j.bpj.2013.02.051
FIGURE 1 The interaction between FGF1, FGFR, and heparin is struc-
turally well characterized with structures of (a) FGF1 bound to heparin hex-
asaccharide (PDB: 2ERM); (b) FGF1 dimerized on heparin decasaccharide
(PDB: 1AXM); (c) the asymmetric FGF1:FGFR2c:heparin complex with
2:2:1 stoichiometry (PDB: 1E0O); and (d) a symmetric 2:2:2
FGF2:FGFR1c:heparin complex (PDB: 1FQ9). In images a–c, one FGF1
molecule and the heparin are in the same orientation. FGF is shown in
cartoon representation and heparin in stick representation.
FGF Ternary Complex Formation 1721a cationic patch formed by both FGF and D2. However, two
different possible modes of dimerization are suggested by
the crystal data. The structure of the complex defined by
Schlessinger et al. (23) (PDB: 1FQ9) contains two 1:1:1
complexes related by a crystallographic twofold axis and di-
merized through direct FGFR-FGFR contacts, as well as
secondary FGF-FGFR and heparin-FGFR interactions
(Fig. 1 d). The two heparin molecules lie in an antiparallel
orientation with their nonreducing ends facing one another
within a cationic canyon formed by dimerization of the
FGF-FGFR. This arrangement raises the question as to
whether both molecules are simultaneously occupying the
canyon in the crystal structure—or whether these two sites
are partially occupied in a way that would be generated by
disorder of two 2:2:1 complexes around the crystallographic
twofold axis. The structure of the complex defined by Pelle-
grini et al. (24) (PDB: 1E0O) contains a similar structure
with a canyon reminiscent of that observed in the 2:2:2
model but with only one heparin molecule, so leading to
a 2:2:1 complex. In addition, an interaction around a heparin
molecule generated by the crystal symmetry gives rise in the
lattice to a different 2:2:1 complex with minimal receptor-
receptor contacts (Fig. 1 c). The heparin is bound primarily
by two FGF molecules in a manner similar to that observed
in the FGF1-octasaccharide crystal structure (22).
It is not clear which architecture is observed in solution or
whether both architectures can form under different circum-
stances. In principle, the 2:2:1 complex can form internally
upon a HS chain, whereas steric hindrance dictates that the2:2:2 complex can only form on the nonreducing ends of
two separate but proximal HS chains.
In previous articles using size exclusion chromatography
(SEC) to study FGF-FGFR-heparin interactions we sug-
gested that formation of the ternary complex may be driven
by cooperative binding of FGFs (FGF1 and FGF2) to
heparin saccharides of sufficient length and sulfation to
dimerize the growth factors (25,26). It has been reported
that the interaction between FGF2 and heparin octasacchar-
ide displays pronounced cooperativity (27). Nondissocia-
tive mass spectrometry, SEC and ultracentrifugation
demonstrated that multiple complexes can form on saccha-
ride chains of physiological length (26,28) with lengths as
short as 16 saccharide units capable of supporting a higher
order complex resembling a 4:4:1 FGF:FGFR:heparin
assembly.
It is clear that more information is needed on the molec-
ular interactions, affinities, and stoichiometries of the
complexes that form during the assembly of the FGF
signaling system in solution. Here we dissect the thermody-
namics of complex formation by investigating the role of
heparin length on FGF1 oligomerization and subsequent
recruitment of the FGFR to form a signaling complex.METHODS
Preparation of components
Recombinant human FGF1 and FGFR2c ectodomain (residues 148–366,
encompassing immunoglobulin-like domains D2 and D3) were prepared
as described in Pellegrini et al. (24). After purification, the proteins were
dialyzed to 10 mM HEPES pH 7.2, 150 mM NaCl. Size-defined oligosac-
charides were prepared from partial heparinase digests of heparin samples
by SEC (17).Isothermal titration calorimetry of FGF-heparin
interactions
Isothermal titration calorimetry (ITC) experiments were performed using
a MicroCal VP-ITC machine (GE Healthcare, Little Chalfont, United
Kingdom). Titrations involved the addition of 10 mL aliquots of ligand
via a rotating stirrer-syringe to the calorimetric cell containing 1.407 mL
of the receptor at 4-min intervals. A constant temperature of 25C and stir-
ring speed of 300 rpm was maintained throughout. A total of 25 injections
per experiment were conducted. Heats of dilution/dissociation determined
in the absence of receptors were subtracted from the titration data before
curve fitting. Additionally, an initial 4 mL injection was discarded from
each dataset to remove the effect of titrant diffusion across the syringe
tip during the equilibration process.Analysis of ITC binding data
Experimental data for the binding of FGF to heparin were fitted to a theoret-
ical model based on the McGhee-von Hippel formalism for the binding of
nonspecific ligands to overlapping binding sites on a monodimensional
lattice (29) modified for the analysis of isotherms (30,31). For the binding
of FGF1 to heparin hexasaccharide, the data were fitted to a noncooperative
model, but for saccharide chains capable of binding more than one FGF1
molecule a cooperative McGhee-von Hippel formalism was employed. InBiophysical Journal 104(8) 1720–1730
1722 Brown et al.the noncooperative model, the heat effect associated with each injection (qi)
is given by Eq. 1,
qi ¼ V0DH

½Mt;iyi 

1 v
V0

½Mt1;i1yi1

; (1)
where V0 is the total cell volume (1.407 mL), [Mt] is the total macromole-
cule concentration, v is the injection volume, and n is the number of ligand
molecules bound per macromolecule, given by Eq. 2,
y ¼ ½X

N  ly
KD

N  ly
N  ðl 1Þy
l1
; (2)
where KD is the dissociation constant, N is the potential number of binding
sites distributed along the molecule, and l is the minimal number of repeat
units necessary to support binding and [X] is the ligand concentration.
The cooperative model considers three different binding modes that
a ligand can adopt on a monodimensional lattice—isolated binding (niso);
binding adjacent to a prebound ligand in a singly contiguous mode (nsc);
and binding with ligands either side in a doubly contiguous mode (ndc) (re-
viewed by Brown (31)). The heat associated with each injection is the
summation of each of these modes given by Eq. 3,
qi ¼V0

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
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
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
þ
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2
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
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;
(3)
where each of the different modes is evaluated as
yiso ¼
½Xt  ½Mty N  lyKD
ð2a1ÞðN  lyÞ þ yR
2ða 1ÞðN  lyÞ
lþ1
;
(4)
  a ðl 1Þy N þ R
ysc ¼ ½Xt  ½Mty 2ða 1Þ KD

ð2a 1ÞðN  lyÞ þ y R
2ða 1ÞðN  lyÞ
l
;
(5)
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ydc ¼ ½Xt  ½Mty 2ða 1Þ KDðN  lyÞ

ð2a 1ÞðN  lyÞ þ y R
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q
R ¼ ðN  ðlþ 1ÞyÞ þ 4ayðN  lyÞ; (7)
where Dh is the enthalpy associated with cooperativity and a is the cooper-
ativity factor.Biophysical Journal 104(8) 1720–1730Isothermal titration calorimetry of FGF-FGFR
interactions
Data for the binding of FGF to FGFR were fitted to a one-site model by
nonlinear least-squares fitting (32) and a full set of thermodynamic param-
eters derived using the relationships shown in Eq. 8,
DG ¼ DH  TDS ¼ RTln

1
KD

; (8)
where DG, DH, and DS are the Gibbs free energy, enthalpy, and entropy of
binding, respectively. T is the absolute temperature and R ¼ 1.98 cal mol1
K1 is the ideal gas law constant.Size-exclusion chromatography
Size-exclusion chromatography (SEC) was performed using a Superdex
200 10/300 HR column (GE Healthcare) equilibrated with 10 mM HEPES
pH 7.2, 150 mM NaCl. All experiments were run on the AKTA Explorer
chromatography system (GE Healthcare) at a flow rate of 0.5 mL min1
and the absorbance at 280 nm was recorded.RESULTS
For complete characterization of the FGF-heparin inter-
action it is necessary to determine the binding affinity, the
binding site size (l), whether ligand binding is cooperative,
and the thermodynamic parameters of both the intrinsic and
cooperative interaction (if present). Using ITC, it is possible
to extract this information using a modified version of
the McGhee-von Hippel formalism (29,30). This model
is appropriate for both cooperative and noncooperative
processes. It has previously been implemented in deter-
mining thermodynamic parameters from ITC data for
proteins binding to chitosan, a linear polysaccharide similar
to heparan sulfate (33). By using defined-length heparin
oligosaccharides similar to those used in structural studies,
it is possible to link the thermodynamics of the FGF-heparin
interaction to the known x-ray and NMR structures.Monovalent FGF-heparin interactions
Homogenously purified FGF1 titrated into a solution of
heparin hexasaccharide gave a sigmoidal profile (Fig. 2 a)
where saturation of heparin binding sites is achieved at
higher FGF1 concentrations. From the NMR structure of
FGF1 bound to heparin hexasaccharide it is known that
only one FGF molecule can bind hexasaccharide concomi-
tantly (20). Therefore, the isotherm was analyzed using
the noncooperative McGhee-von Hippel model for nonspe-
cific binding to a monodimensional lattice (Eq. 1), as 1:1
interactions are devoid of cooperative processes. In this,
and all subsequent analyses, the value of N was fixed. N
reflects the number of repeating units per macromolecule,
which in the case of FGF binding to carbohydrates is the
number of saccharide moieties. Therefore, in the analysis
FIGURE 2 Analysis of FGF1-heparin hexasac-
charide interaction by direct (a) and reverse (b)
titrations. In the direct titration, 100 mM FGF1
was titrated into 7 mM hexasaccharide and in the
reverse titration, 100 mM heparin was titrated into
12.5 mM FGF1. (Upper panel) Calorimetric titra-
tion trace with the integrated isotherms (shown in
lower panel). (Solid lines) Best fit to the noncoop-
erative McGhee-von Hippel model. (c) Thermody-
namic dissection of the interaction between FGF1
and heparin hexasaccharide. (Shading) Free energy
of binding (DG); (crosshatch) enthalpy of binding
(DH); (diagonal shading) entropy of binding
(TDS).
FGF Ternary Complex Formation 1723of monovalent interactions N was set at 6.0, reflecting the
six saccharide moieties present.
The binding site length was determined as 4.7 saccharide
units, the affinity as low micromolar (1.9 mM) with an
enthalpy of 5.0 kcal mol1. From these values, DG and
DS were obtained (Table 1).
By performing reverse titrations, where the titrant and ti-
trand orientations are reversed, the stoichiometry and the
suitability of the binding model can be checked. For mono-
valent biomolecular reactions it is expected that the
measured thermodynamic parameters are invariant whenTABLE 1 ITC-derived thermodynamic parameters for the binding o
Titration KD (mM) DG (kcal mol
1) DH (kcal mol1)
FGF1–6-mer 1.9 5 0.2 7.8 5.05 0.1
6-mer-FGF1 1.1 5 0.2 8.1 4.55 0.0
FGF1–8-mer 1.1 5 0.1 8.1 5.75 0.0
8-mer-FGF1 3.0 5 0.2 7.5 6.85 0.0
FGF1–16-mer 1.2 5 0.1 8.1 8.85 0.0
16-mer-FGF1 1.55 0.2 7.9 9.0 þ 0.1
In all cases, the number of repeat units, N, was fixed as the number of sacchari
asaccharide (6-mer) to FGF1 was analyzed using the noncooperative McGhee-v
ativity (Dh) are not applicable (n.a.). The binding of FGF1 to heparin 8-mer anchanging the orientation of the experiment. However, this
is often not the case as one species may display greater
aggregation when concentrated. If the stoichiometry is not
1:1 and the binding sites are not equivalent or demonstrate
cooperativity, comparison of both experiments reveals
substantial differences in the titration profile.
Analysis of the reverse titration of heparin hexasacchar-
ide to FGF1 (Fig. 2 b) reveals FGF1 binds with an affinity
of 1.1 mM to a minimal footprint of 5.0 saccharide units.
The value is greater than observed for the forward titration
(4.7) with variations in this parameter reflecting the factf heparin saccharides of defined length to FGF1
TDS (kcal mol1) l (moieties) a Dh(kcal mol1)
2.80 4.75 0.1 n.a. n.a.
3.6 5.05 0.2 n.a. n.a.
2.4 3.75 0.1 7.05 0.3 3.0 5 0.2
0.7 4.75 0.2 4.55 0.1 2.6 5 0.2
0.7 3.85 0.1 6.15 0.0 1.8 5 0.3
1.1 3.15 0.3 5.25 0.0 1.7 5 0.3
de moieties present in the heparin molecules. The binding of heparin hex-
on Hippel formalism, for which cooperativity (a) and enthalpy of cooper-
d 16-mer were analyzed with the cooperative model.
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1724 Brown et al.that l is a composite of not only the real stoichiometry, but
also differences in the active concentration of FGF1 from
the measured total concentration. These discrepancies may
be accentuated as concentration and heterogeneity effects
due to heparin also contribute to the value of l as Nwas fixed
during the fitting procedure.FGF-heparin thermodynamics
ITC accurately determines the thermodynamic contributions
of enthalpy (DH) and entropy (TDS) changes to free ener-
gies of binding (DG). Physical phenomena that contribute
to the enthalpy term include van der Waals, hydrogen
bonding, and electrostatic complementarity. Changes in
conformational and configuration space (roto-translational
entropy) and solvation upon complex formation contribute
to the entropy term (34). Interpretation of thermodynamics
alongside published crystal structures allows insight into
the processes of complex formation. The thermodynamic
profiles for both the normal and reverse titration of heparin
hexasaccharide with FGF1 are shown in Fig. 2 c.
The binding of FGF1 to heparin hexasaccharide is driven
by both enthalpy (DH ¼ 5.0 kcal mol1) and entropy
(TDS ¼ 2.8 kcal mol1). A similar favorable entropic
contribution of 22 kcal mol1 was estimated from the
NMR order parameters of the FGF1-hexasaccharide inter-
action (35). The enthalpy term reflects the strong, ionic
interactions that form between the side chains of basic
residues in the three surface loops of the heparin binding
site and the sulfate and carboxylate groups of heparin. As
well as ionic interactions, the FGF1-heparin interaction
is also stabilized by hydrogen bonds and van der Waals
interactions.Biophysical Journal 104(8) 1720–1730Divalent FGF-heparin interactions
To investigate the reported formation of a heterotrimer of
two FGF1 molecules on a single heparin fragment when
oligosaccharides greater than six moieties in length are
available (22), homogeneously purified FGF1 was titrated
to a solution of octasaccharide. The titration profile is
biphasic (Fig. 3 a). The apparent maximal number of ligand
molecules bound per macromolecule can be inferred from
the localization of the inflection point of the titration plot.
The inflection point of the octasaccharide to FGF1 titration
is ~2.0, suggesting that heparin octasaccharide is capable of
binding two FGF1 molecules concomitantly. Therefore, the
data were analyzed according to the McGhee-von Hippel
model for cooperative data, with N fixed at 8.0, reflecting
the eight saccharide moieties present in the heparin
octasaccharide.
The minimal footprint required to support FGF1 binding,
determined from the titration of FGF1 to heparin hexasac-
charide, is approximately five saccharide moieties. How-
ever, previous studies have suggested that four saccharide
units are the minimal footprint. In either case, a heparin
octasaccharide is theoretically incapable of binding more
than two FGF1 molecules concomitantly. The McGhee-
von Hippel model for cooperative binding assumes that
a ligand is capable of binding to a lattice in three modes: iso-
lated (iso), singly contiguous (sc), and doubly contiguous
(dc). However, in the binding of FGF1 to octasaccharide,
it is not possible to have doubly contiguous FGF1, as
it would require three FGF1 molecules bound to a single
octasaccharide. Therefore, only isolated and singly contig-
uous binding modes (Eqs. 4 and 5) were used to evaluate
the normalized heat effect upon binding.FIGURE 3 Analysis of FGF1-heparin octasac-
charide interaction by direct (a) and reverse (b)
titrations. In the direct titration, 100 mM FGF1
was titrated into 7 mM octasaccharide and in
the reverse titration, 100 mM octasaccharide was
titrated into 12.5 mM FGF1. (Upper panel) Calori-
metric titration trace with the integrated isotherms
(shown in lower panel). (Solid lines) Best fit to the
cooperative McGhee-von Hippel model.
FGF Ternary Complex Formation 1725The McGhee-von Hippel model was proposed for a
linear array of binding sites, in which neighboring mole-
cules sit adjacent to one another. However, heparin is
a helical molecule that presents linear arrays of binding
sites on opposing sides of the molecule (36). Therefore,
assuming FGF1 binds heparin in the trans configuration
observed in the crystal structures (22), the Dh term is
not the enthalpy associated with the direct interaction
between neighboring bound ligands, but rather the enthalpy
change associated with interactions mediated through
heparin.
After fitting, the affinity of the interaction was determined
to be 1.1 mM, which is slightly higher than the affinity of
FGF1 for heparin hexasaccharide (1.9 mM). This may be
due to the presence of additional saccharide moieties that
form supplementary interactions to those observed in the
FGF1-6-mer interaction. The enthalpy of binding is slightly
greater, again reflecting the presence of additional contacts
(5.7 kcal mol1, compared with 5.0 kcal mol1). There
is a compensatory decrease in the entropic term (2.4
compared to 2.8 kcal mol1), however, it is still favorable,
suggesting that interface desolvation is still a considerable
factor despite the formation of a higher molecular weight
species (2:1) that might be expected to have a negative effect
on the entropic contribution.
The McGhee-von Hippel model allows cooperative
parameters to be measured. The binding of FGF1 to heparin
octasaccharide displays positive cooperativity (a ¼ 7.0).
Interestingly, the positive cooperativity is not driven by
enthalpy but rather by entropy with Dh determined as
~3 kcal mol1. Entropy-driven positive cooperativity is
consistent with binding of one FGF1 molecule restricting
the number of conformations heparin can adopt, favoring
a conformation suitable for FGF binding. The affinity of
the second FGF1 molecule is given by aKD ¼ 157 nM
(DG ¼ 9.3 kcal mol1). Thus, formation of a heparin-
linked FGF1 dimer is strongly favored over the formation
of 1:1 complexes.
To characterize further the interaction, the experiment
was performed in reverse, in which FGF1 was titrated to
heparin octasaccharide (Fig. 3 b). The concentrations of
FGF1 and heparin were consistent with those used for the
reverse titration of hexasaccharide to FGF1. Therefore,
direct comparison of Figs. 2 b and 3 b clearly demonstrates
that saturation is achieved much earlier due to the ability of
octasaccharide to dimerize FGF1 (the inflection point is
~0.5, consistent with a 2:1 stoichiometry).
After fitting, the binding affinity was determined to
be 3.0 mM, which is lower than observed in the direct
titration. Alongside the lower intrinsic affinity, the coopera-
tivity parameter (a) was determined as 4.5. Therefore,
the affinity of the second FGF1 molecule is 667 nM
(DG ¼ 8.4 kcal mol1). The cooperative interaction has
a Dh of 2.6 kcal mol1, which is again lower than that ob-
tained from the direct titration.Having determined that the binding of FGF1 to heparin
hexa- and octasaccharide is 1:1 and 2:1, respectively, the
data were reanalyzed using one-site and two-site binding
models to see whether the data could be equally well ex-
plained with simpler models. The results of the data fitting
are shown in Fig. S1 and Table S1 in the Supporting
Material. While the 1:1 interaction can be modeled using
a simplistic model, the biphasic FGF1-8-mer data cannot.
This demonstrates there is a need to fit this with a model
that takes into consideration cooperativity and overlapping
binding sites, for which the McGhee-von Hippel model is
the most appropriate.Oligomeric FGF-heparin interactions
The binding of FGF1 to heparin octasaccharide was
modeled according to the McGhee-von Hippel model with
the restriction that a maximum of two FGF1 molecules
can bind the heparin fragment simultaneously. This model
was validated by calculation of the maximal number of
ligand molecules bound per macromolecule as N/l ¼
8/3.74 ¼ 2.13. In the restricted model, FGF1 molecules
were only permitted to exist in either isolated or singly
contiguous bound states. To investigate the influence of
the ability of FGF1 to bind in a doubly contiguous state,
the binding of FGF1 to heparin 16-mer was investigated.
Based on the assumption that l is ~4, a 16-mer is theoreti-
cally capable of binding four FGF1 molecules.
FGF1 was titrated to heparin 16-mer in the calorimetric
cell. To permit saturation while avoiding significant dilution
effects due to high concentrations, 100 mM FGF1 was
titrated into just 2.5 mM heparin. Despite the low concentra-
tion of macromolecule, the heat event was still sufficiently
exothermic to permit a good signal/noise ratio. The isotherm
displayed complex multiphasic behavior, therefore to allow
full characterization of the isotherm, the number of injec-
tions was increased to 40, with a compensatory decrease
in injection volume to 6 mL. The resulting isotherm is shown
in Fig. 4.
The intrinsic affinity of FGF1 for heparin was determined
as 1.2 mM, in agreement with previously determined values.
The minimal length of heparin saccharide units capable of
supporting FGF1 binding (l) is 3.8, validating the assump-
tion that approximately four FGF1 molecules can bind
heparin 16-mer simultaneously. Therefore, FGF1 molecules
can bind in all three possible states.
The progression of saturation is shown in Fig. 4 c.
Initially isolated bound FGF1 species dominate, due to the
large excess of macromolecule to FGF1. However, as the
titration proceeds, the presence of positive cooperativity
ensures that the population of singly and doubly contiguous
species increase rapidly. At the titration midpoint, virtually
no 1:1 complexes persist, with the population of doubly
contiguous bound species dominating. At saturation, the
majority of species are doubly contiguous (>80%). TheseBiophysical Journal 104(8) 1720–1730
FIGURE 4 ITC analysis of FGF1-heparin 16-
mer by direct (a) and reverse (b) titrations. A trace
of calorimetric titration (upper panel) and inte-
grated isotherms (lower panel). Solid lines repre-
sent the best fit to the cooperative McGhee-von
Hippel model. (c) The evolution of the number
of ligand molecules bound, n, are shown as the
summation of those bound in an isolated state
(niso); those bound in a singly contiguous state
(nsc) and those in a doubly-contiguous state (ndc)
are plotted as a function of the molar ratio for the
direct titration of FGF1 to heparin 16-mer. (Inset)
A theoretical model of four FGF molecules bound
to heparin 16-mer showing two linear arrays in
which doubly-contiguous molecules are in cis
and trans conformations.
1726 Brown et al.doubly contiguous species can be in both cis and trans
orientations.
The interaction is again characterized by nonenthalpy-
driven positive cooperativity. The best fit to the data was
obtained with a cooperativity parameter of 6.1 (a value of
7.0 was obtained for the FGF1–8-mer direct titration) and
a Dh of 1.80 kcal mol1. The enthalpy due to cooperativity
is less positive than that observed in the 8-mer-FGF1 titra-
tion. This may result from FGF1 being able to bind in
both trans and cis orientations on the longer chain of
heparin—modes of binding that may have different thermo-
dynamics. In the ITC experiment it is only possible to
determine the macroscopic cooperativity enthalpy, i.e., the
overall enthalpy; it is not possible to separate the individual
binding events.
The reverse titration is shown in Fig. 4 b. The intrinsic
affinities and thermodynamics are similar to that observed
in the direct titration. Similarly, the cooperativity parame-
ters (a ¼ 5.2 and Dh ¼ 1.7 kcal mol1) are in very close
agreement with those obtained in the direct titration (6.1
and 1.8 kcal mol1, respectively).Biophysical Journal 104(8) 1720–1730Thermodynamic assembly of FGF1:FGFR2c:
heparin ternary complex
FGF1 titrated into FGFR2c ectodomain (Fig. 5 a) produces
a hyperbolic rather than sigmoidal curve, which does not
allow precise determination of stoichiometry. For curve
fitting, n was fixed at 1.0, reflecting the 1:1 stoichiometry
observed in the crystal structure (37) with the resulting
values given in Table 2. The interaction has a KD
of 4.3 mM, which is weaker than previously reported
(0.5 mM (38)), and is enthalpy-driven (DH ¼ 14.7 kcal
mol1), as ~2400 A˚2 of accessible surface is buried upon
formation of the binary complex (37).
FGF1 was then preincubated with hexasaccharide in a
1:1 stoichiometry. The titration of this complex into FGFR2c
ectodomain (Fig. 5 b, Table 2) shows a binding stoichiometry
of 1:1 (n¼ 0.9). Themeasured affinity is 325 nM,which is an
order of magnitude greater than for the formation of the
binary complex in the absence of heparin. The interaction
has both favorable enthalpy and entropy terms (DH ¼
5.6 kcal mol1,TDS ¼ 3.3 kcal mol1). The favorable
FIGURE 5 ITC analysis of FGF1 binding to FGFR2c in the absence (a) and presence of heparin hexa- (b) and octasaccharide (c). To determine the inter-
action between FGF1 and FGFR2c, 100 mMFGF1 was titrated into 10 mMFGFR2c. For panel b, 125 mM complex of FGF1–6-mer preincubated in a 1:1 ratio
was titrated into 10 mMFGFR2c and for panel c, 100 mMFGF1–8-mer complex was titrated into 10 mM receptor. Trace of calorimetric titration (upper panel)
and integrated isotherms (lower panel). (Solid lines) Best fit to a one-site model. For analysis of the FGF1-FGFR2c titration, n was fixed as 1.0.
FGF Ternary Complex Formation 1727entropy term is presumably a result of expulsion of structured
waters to bulk. In comparison, the binary interaction shows
a greater enthalpic contribution, while being less reliant on
the entropic term. The simple heat evolution does not provide
evidence for a secondary heat event caused by the dimeriza-
tion of the two 1:1:1 complexes, as might be expected from
the model proposed by Schlessinger et al. (23), but does
not explicitly rule out the possible formation of a 2:2:2
complex.
The titration of FGF1 dimerized on heparin octasacchar-
ide to FGFR2c (Fig. 5 c, Table 2) shows a binding stoichi-
ometry of 1:2. This concurs with the 2:2:1 model (24),
where the central FGF1-dimer dimerizes FGFR2c. The
interaction between FGF1-8-mer and FGFR2c displays
a high enthalpic term (DH ¼ 26.2 kcal mol1), but with
a large positive entropic contribution (TDS ¼ 18.2 kcal
mol1). It should be noted that within the calorimetric
cell, several additional association and dissociation eventsTABLE 2 ITC-derived thermodynamic parameters for the
binding of FGF1 to FGFR2c in the absence and presence of
heparin hexa- and octasaccharide
Titration
KD
a
(nM)
DG
(kcal mol1)
DHb
(kcal mol1)
TDS
(kcal mol1) nc
FGF1-FGFR2c 4310 7.2 6.9 0.3 1.0
[FGF1:6-mer]-
FGFR2c
325 9.9 5.6 3.3 0.9
[FGF1:8-mer]-
FGFR2c
826 8.0 26.2 18.2 2.4
aErrors in KD are <14.0%.
bErrors in DH are <4.5%.
cErrors in experimentally derived values of n are <3.5%.might be occurring simultaneously alongside the FGF-
heparin to FGFR association (FGF-heparin dissociation
and association; FGF binding to FGFR and FGFR-heparin
association).
To confirm the stoichiometry of the complexes formed
during the titration experiments, the products were analyzed
by SEC (Fig. 6). We have previously shown that analysis
by SEC is sufficient to determine FGF-FGFR-heparin stoi-
chiometries consistent with those from nondissociative
mass spectrometry and analytical ultracentrifugation (26).
Molecular weights of the complexes were estimated fromFIGURE 6 The products of the ITC experiments were applied to a Super-
dex 200 10/300 column equilibrated with 20 mM Tris pH 8.0, 150 mM
NaCl. Absorbance of the eluate was monitored at 280 nm. Peak labeling:
(i) 1:1 FGF1:heparin hexasaccharide; (ii) 1:1:1 FGF1:FGFR2c:heparin
hexasaccharide; 1), 2:1 FGF1:heparin octasaccharide; and 2), 2:2:1
FGF1:FGFR2c:heparin octasaccharide.
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1728 Brown et al.the peak elution volumes after column calibration. The re-
sulting product of the titration of preformed FGF1-6-mer
complex to a suspension of FGFR2c shows two peaks
corresponding to a 1:1:1 FGF1:FGFR2c:6-mer heparin
complex and, as the titrant is added to excess, the 1:1
complex of FGF1-6-mer. The resulting product of the titra-
tion of preformed 2:1 FGF1-8-mer heparin complex with
FGFR2c is consistent with a 2:2:1 complex and excess
titrant. No higher order species were observed.DISCUSSION
FGF signaling requires the formation of a ternary complex
consisting of FGF, FGFR, and HS. However, the stoichiom-
etry and architecture of this complex in solution remains
unclear, with crystal structures suggesting alternative modes
of interaction are possible. The role of HS cannot be defined
with biophysical and structural studies utilizing mostly
small heparin fragments of unphysiological length. Longer
HS chains, such as those that occur in vivo, are capable of
oligomerizing FGFs with a 16-kDa chain capable of binding
11–15 molecules of FGF1 (38,39). Several studies have also
attempted to establish the minimal length of HS/heparin
required for FGF binding and oligomerization.While a tetra-
saccharide is capable of binding FGF1, saccharides shorter
than an octasaccharide cannot facilitate dimerization and
support a strong mitogenic signal (22,25,40–42). However,
different FGFs may have different length requirements.
Previous attempts to determine the binding of FGFs
to heparan sulfate analogs by ITC have typically not
taken into consideration the repetitive nature of heparin
(38,43,44). Guzma´n-Casado et al. (45) have previously
suggested that FGF1 interacts with heparin noncoopera-
tively. This study used a heterogeneous commercial prepa-
ration of heparin with an average molecular mass of
3000 g mol1, which was suggested as comprising heparin
molecules between 8 and 10 saccharide units in length. In
their analysis using a binding polynomial equation it was
assumed that these molecules would present two FGF-
binding sites that are identical and independent. However,
such a model does not take into consideration overlapping
binding sites and assumes the length of the binding foot-
print. The FGF1-octasaccahride crystal structure clearly
shows two FGF1 protomers making different contacts
with heparin, therefore the FGF1 binding sites cannot be
considered identical.
Here, we have used McGhee-von Hippel formalism to
dissect the thermodynamic profile and stoichiometry of
FGF1 binding to heparin fragments of defined length.
FGF1 has a binding footprint of 4.2 saccharide units (the
mean of all values of l determined from both forward and
reverse titrations of FGF1 with different heparin fragments).
Consistent with this, the data suggest that a heparin octasac-
charide is the shortest fragment capable of forming a 2:1
heterotrimer, whereas hexasaccharide is only able to bindBiophysical Journal 104(8) 1720–1730in a 1:1 stoichiometry. The average intrinsic affinity of
FGF1 for heparin was determined as 1.6 mM, which is lower
than previously reported by Spivak-Kroizman et al. (38), as
prior measurements have not taken into consideration the
statistical effect of increasing the number of overlapping
binding sites available. However, the intrinsic affinity of
FGF1 for heparin is greater than that of Heparin Cofactor
II, a coagulation factor, that binds with an affinity of
640 mM as determined by applying the McGhee-von Hippel
model to fluorescence data (46).
The data presented here demonstrate that FGF1 binding
to heparin is facilitated by positive cooperativity. This
agrees with the observation that FGF1 preferentially forms
oligomers rather than 1:1 complexes in the presence of
long-chain heparins (25). Previous studies have also shown
that the binding of FGF2 to heparin octasaccharide is coop-
erative (27,42), suggesting cooperative binding to heparin is
not limited to FGF1. Saxena et al. (27) used NMR 1H T2
measurements to record binding curves for the stepwise
titration of heparin octasaccharide to FGF2. Using a two-
step model, they determined that the first molecule of
FGF2 bound with an affinity of 100 nM and the second
with an affinity of 5.8 nM. However, this, and their corre-
sponding ITC data, did not take into consideration the fact
that heparin acts as a monodimensional lattice in which
the binding sites are not necessarily distinct. Upon taking
this into consideration, we show that the second FGF1 mole-
cule binds with an approximate sixfold higher affinity than
the first. Similar positive cooperativity determined by appli-
cation of the McGhee-von Hippel model to ITC data has
been observed for the binding of proteins to chitosan,
another monodimensional lattice (33). This suggests the
possibility of a consistent mechanism whereby carbohydrate
chains promote oligomerization through positively coopera-
tive mechanisms.
The FGF-heparin positive cooperativity is mediated
through more favorable entropy. Mechanisms of cooperativ-
ity generally involve electrostatic coupling, lowering of the
entropic penalty, and/or conformational changes. Given that
there is no significant conformational change in FGF1
tertiary structure upon binding heparin (19), any positive co-
operativity due to conformational changes must be mediated
through the heparin molecule. In solution, heparin forms
a relatively rigid helical conformation with dyad symmetry
(36). Detailed conformational analysis of all FGF-heparin
cocrystals revealed that FGF induces a localized kink in
heparin (21). This change in backbone torsion angles occurs
at the trisaccharide level and is enhanced by the ability of
the iduronic acid to adopt multiple ring formations, with
the kink augmented by the 1C4 conformation. In FGF1-
heparin structures the kink is closer to the reducing end
and spans three monosaccharide units where the iduronate
is flanked by two glucosamines. The kink permits optimal
ionic and van der Waals contact with the FGF, while main-
taining the overall 21 helical symmetry.
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octasaccharides and oligomerization on large HS chains
is probably key to subsequent receptor dimerization and
potentiation of receptor signaling. However, this assumption
is only true if FGF1 binds heparin before interacting with
FGFR. Previously reported Kon rates from surface plasmon
resonance favors the formation of an initial FGF-heparin
complex (47). For FGF2, the Kon rate for heparin was
1.1  107 M1 s1, compared to 9.6  104 M1 s1 for
the interaction with the receptor (FGFR1) in the absence
of heparin. This suggests that, after secretion, FGF is
concentrated upon cell surface HS. This concentration effect
is physiologically important, as exceptionally low concen-
trations of FGF are capable of signaling (48).
What effect does trans-dimerization have on FGFR
recruitment? In comparison with the formation of the binary
complex (4.3 mM), the octasaccharide-dimerized FGF1
binds FGFR2c with a higher affinity (826 nM) and permits
FGFR dimerization as shown both in the midpoint of the
titration curve and also by SEC. The architecture presum-
ably adopts that of the 2:2:1 complex with a central
heparin-mediated FGF1 dimer sequestering two FGFR2c
molecules. Dimerization of the binary complex cannot
occur in the absence of heparin (28,38), and in solution,
we do not observe formation of a 2:2:2 complex even with
heparin hexasaccharide present. Each FGF1:6-mer complex
only recruits a single FGFR to form a 1:1:1 complex. The
absence of evidence of a 1:1:1 dimerization mediated by
FGF and FGFR interactions suggests that FGF1, when
already assembled on heparin hexasaccharide, cannot stim-
ulate FGFR dimerization, as might be expected from the
2:2:2 complex. However, it is possible that formation of
this complex may occur by a separate pathway in which
FGF1 is not already bound to heparin, or may only form
on HS that features sulfation patterns at the nonreducing
ends that do not permit FGF1 dimerization.
In conclusion, the observations described here favor a pre-
assembly model in solution where FGF1 is first bound to
heparin in a trans-dimeric manner before the recruitment
of two FGF receptors and the activation of the signaling
response. The absence of evidence of a 2:2:2 dimerization
mediated by FGFR and FGF interactions in solution does
not preclude its existence at the membrane, as it can coexist
with the 2:2:1 complex assembled on heparin. In this case,
a two-dimensional cluster of FGFR, FGF, and heparin will
assemble, which may mediate the activation of signaling
pathways and/or receptor-mediated endocytosis.SUPPORTING MATERIAL
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